Badih Junior Daou

Badih Junior Daou

Auto-generated profile, based on publicly available information

Badih Junior Daou

Departments of Neurosurgery, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
BDBadih J. Daou
Badih J. Daou
SKSravanthi Koduri
Sravanthi Koduri
BTB. Gregory Thompson
B. Gregory Thompson
NCNeeraj Chaudhary
Neeraj Chaudhary
APAditya S. Pandey
Aditya S. Pandey
Aneurysmal subarachnoid hemorrhage (aSAH) continues to be associated with significant morbidity and mortality despite advances in care and aneurysm treatment strategies. Cerebral vasospasm continues to be a major source of clinical worsening in patients. We intended to review the clinical and experimental aspects of aSAH and identify strategies that are being evaluated for the treatment of vasospasm. A literature review on aSAH and cerebral vasospasm was performed. Available treatments for aSAH continue to expand as research continues to identify new therapeutic targets. Oral nimodipine is the primary medication used in practice given its neuroprotective properties. Transluminal balloon angioplasty is widely utilized in patients with symptomatic vasospasm and ischemia. Prophylactic “triple‐H” therapy, clazosentan, and intraarterial papaverine have fallen out of practice. Trials have not shown strong evidence supporting magnesium or statins. Other calcium channel blockers, milrinone, tirilazad, fasudil, cilostazol, albumin, eicosapentaenoic acid, erythropoietin, corticosteroids, minocycline, deferoxamine, intrathecal thrombolytics, need to be further investigated. Many of the current experimental drugs may have significant roles in the treatment algorithm, and further clinical trials are needed. There is growing evidence supporting that early brain injury in aSAH may lead to significant morbidity and mortality, and this needs to be explored further.

26 November 2015 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
BDB. Daou
B. Daou
RSR. M. Starke
R. M. Starke
NCNohra Chalouhi
Nohra Chalouhi
STStavropoula Tjoumakaris
Stavropoula Tjoumakaris
DHDavid Hasan
David Hasan
PJPascal Jabbour
Pascal Jabbour
BACKGROUND AND PURPOSE: The use of the Pipeline Embolization Device in the management of recurrent previously stented cerebral aneurysms is controversial. The aim of this study was to evaluate the efficacy and safety of the Pipeline Embolization Device in the treatment of recurrent, previously stented aneurysms. MATERIALS AND METHODS: Twenty-one patients with previously stented recurrent aneurysms who later underwent Pipeline Embolization Device placement (group 1) were retrospectively identified and compared with 63 patients who had treatment with the Pipeline Embolization Device with no prior stent placement (group 2). Occlusion at the latest follow-up angiogram, recurrence and retreatment rates, clinical outcome, complications, and morbidity and mortality observed after treatment with the Pipeline Embolization Device were analyzed. RESULTS: Patient characteristics were similar between the 2 groups. The mean time from stent placement to recurrence was 25 months. Pipeline Embolization Device treatment resulted in complete aneurysm occlusion in 55.6% of patients in group 1 versus 80.4% of patients in group 2 (P = .036). The retreatment rate in group 1 was 11.1% versus 7.1% in group 2 (P = .62). The rate of good clinical outcome at the latest follow-up in group 1 was 81% versus 93.2% in group 2 (P = .1). Complications were observed in 14.3% of patients in group 1 and 9.5% of patients in group 2 (P = .684). CONCLUSIONS: The use of the Pipeline Embolization Device in the management of previously stented aneurysms is less effective than the use of this device in nonstented aneurysms. Prior stent placement can worsen the safety and efficacy profile of this device.

1 August 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
BDBadih J. Daou
Badih J. Daou
GPGregory Palmateer
Gregory Palmateer
BTB. Gregory Thompson
B. Gregory Thompson
CMCormac O. Maher
Cormac O. Maher
JHJames A. Hayman
James A. Hayman
APAditya S. Pandey
Aditya S. Pandey

4 June 2020 in Neurosurgery
Verified
Journal Article
Closed access
APAditya S Pandey
Aditya S Pandey
BDBadih J Daou
Badih J Daou
JTJenny P Tsai
Jenny P Tsai
SZSyed F Zaidi
Syed F Zaidi
HSHisham Salahuddin
Hisham Salahuddin
JSJulie Shawver
Julie Shawver

19 November 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
BDB.J. Daou
B.J. Daou
GPG. Palmateer
G. Palmateer
DWD.A. Wilkinson
D.A. Wilkinson
BTB.G. Thompson
B.G. Thompson
CMC.O. Maher
C.O. Maher
APA.S. Pandey
A.S. Pandey
BACKGROUND AND PURPOSE: T2 signal and FLAIR changes in patients undergoing stereotactic radiosurgery for brain AVMs may occur posttreatment and could result in adverse radiation effects. We aimed to evaluate outcomes in patients with these imaging changes, the frequency and degree of this response, and factors associated with it. MATERIALS AND METHODS: Through this retrospective cohort study, consecutive patients treated with stereotactic radiosurgery for brain AVMs who had at least 1 year of follow-up MR imaging were identified. Logistic regression analysis was used to evaluate predictors of outcomes. RESULTS: One-hundred-sixty AVMs were treated in 148 patients (mean, 35.6 years of age), including 42 (26.2%) pediatric AVMs. The mean MR imaging follow-up was 56.5 months. The median Spetzler-Martin grade was III. The mean maximal AVM diameter was 2.8 cm, and the mean AVM target volume was 7.4 mL. The median radiation dose was 16.5 Gy. New T2 signal and FLAIR hyperintensity were noted in 40% of AVMs. T2 FLAIR volumes at 3, 6, 12, 18, and 24 months were, respectively, 4.04, 55.47, 56.42, 48.06, and 29.38 mL Radiation-induced neurologic symptoms were encountered in 34.4%. In patients with radiation-induced imaging changes, 69.2% had new neurologic symptoms versus 9.5% of patients with no imaging changes (P = .0001). Imaging changes were significantly associated with new neurologic findings (P < .001). Larger AVM maximal diameter (P = .04) and the presence of multiple feeding arteries (P = .01) were associated with radiation-induced imaging changes. CONCLUSIONS: Radiation-induced imaging changes are common following linear particle accelerator–based stereotactic radiosurgery for brain AVMs, appear to peak at 12 months, and are significantly associated with new neurologic findings.

1 August 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
DWD. Andrew Wilkinson
D. Andrew Wilkinson
SKSravanthi Koduri
Sravanthi Koduri
SASharath Kumar Anand
Sharath Kumar Anand
BDBadih J. Daou
Badih J. Daou
VSVikram Sood
Vikram Sood
APAditya S. Pandey
Aditya S. Pandey